WAVEMAN · COMPANY

EW · Edwards Lifesciences Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

EW

Name: Edwards Lifesciences Corp (EW) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Edwards Lifesciences Corp

MEDICAL DEVICES · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · CIK 0001099800

FORM 144 · 9☆ WATCH

INSIDER NET · 180D

-$15.5M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

643

13F, latest reported quarter

REVENUE GROWTH

+11.5%

XBRL, annual

NET MARGIN

17.7%

CONVERSIONS · 180D

codes C/M, not in net · $7.1M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$15.5M over 180 days

-$4.6M over 90 days

below 89% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

643 funds added or opened last quarter

more than 94% of Medical Devices

REVENUE

+11.5% year over year

more than 58% of Medical Devices

MARGIN

17.7% net margin

more than 91% of Medical Devices

BUYBACKS

$575.1M repurchased, FY to 2026-06-30

more than 87% of Medical Devices

SHORT

1.7% of shares outstanding short · 1.8 days to cover · settled 2026-07-31

below 67% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$15.5M across 8 people in 180 days.

643 funds added or opened positions in the latest 13F quarter, of 1,342 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +9.8%

+9.8%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $15.5M sold by insiders over 180 days, 643 funds added last quarter, $9.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM TMDX OM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Edwards Lifesciences Corp insiders sold a net $15.5M of stock across 383 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Dahl Andrew M.

SVP, Corporate Controller

SELL

2026-08-31

544.0

$49.5K

Bruls Annette

CVP, EMEACLA

SELL

2026-08-28

2,644.0

$237.9K

Markowitz Wayne

CVP, JAPAC

SELL

2026-08-26

1,240.0

$113.4K

Chopra Daveen

CVP, TMTT, Surgical & IHFM

SELL

2026-08-26

1,154.0

$105.9K

Chopra Daveen

CVP, TMTT, Surgical & IHFM

SELL

2026-08-26

30,646.0

$2.8M

383 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 378 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

58,789,433.0 sh

$5.3B

VANGUARD CAPITAL MANAGEMENT LLC

37,615,952.0 sh

$3.4B

VANGUARD PORTFOLIO MANAGEMENT LLC

26,411,402.0 sh

$2.4B

STATE STREET CORP

26,321,940.0 sh

$2.4B

JPMORGAN CHASE & CO

22,783,175.0 sh

$2.1B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Dahl Andrew M.

FILED 2026-08-31

$49.5K

Bruls Annette

FILED 2026-08-28

$237.9K

Chopra Daveen

FILED 2026-08-26

$2.9M

Markowitz Wayne

FILED 2026-08-26

$113.4K

Lippis Daniel J.

FILED 2026-08-11

$170.9K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Medical Technology and Devices Portfolio

$204.1M POSITION · AS OF 2026-02-28

5.6%

iShares Health Innovation Active ETF

$478.1K POSITION · AS OF 2026-04-30

4.7%

iShares U.S. Medical Devices ETF

$141.7M POSITION · AS OF 2026-03-31

4.5%

Artisan Focus Fund

$44.5M POSITION · AS OF 2026-03-31

3.9%

The Future Fund Long/Short ETF

$1.4M POSITION · AS OF 2026-02-28

3.6%

VANGUARD GLOBAL ESG SELECT STOCK FUND

$49.3M POSITION · AS OF 2026-04-30

3.3%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 83 registered trials, 45 still enrolling or running — a status change here is dated weeks before the press release

Not applicable

45 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Edwards Lifesciences Political Action Committee (A.K.A. Edwards Pac)

CYCLE 2026 · $297K SPENT

$273.6K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$6.1B	$5.4B	$5.0B	$4.5B
GROSS PROFIT	$4.7B	$4.3B	$4.0B	$3.7B
OPERATING INCOME	$1.3B	$1.4B	$1.3B	$1.5B
NET INCOME	$1.1B	$4.2B	$1.4B	$1.5B
EPS (DILUTED)	1.83	6.97	2.30	2.44
OPERATING CASH FLOW	$1.6B	$542.3M	$895.8M	$1.2B
CASH	$2.9B	$3.0B	$1.1B	$769.0M
LONG-TERM DEBT	$598.3M	$597.7M	$597.0M	$596.3M
BUYBACKS	$893.4M	$1.2B	$879.6M	$1.7B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE